Combined Physicians Lab LLC

Combined Physicians Lab LLC was paid $7.42M by Medicaid between Jan 2018 and Dec 2024, across 37 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 28% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kentucky

Rank by total paid#13 of 73

Median peer was paid$95K

This provider vs. median78×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,911	$18K
2019	5,497	$15K
2020	5,440	$18K
2021	23,349	$1.40M
2022	31,547	$1.77M
2023	43,539	$1.71M
2024incomplete	63,072	$2.48M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	28%	50,853	33,123	$2.09M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	28%	36,364	19,199	$2.07M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	15%	43,668	25,364	$1.12M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	15%	16,334	11,620	$1.09M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	12%	9,999	6,979	$908K
80053	Comprehensive metabolic panel	<1%	3,377	3,171	$18K
87501		<1%	607	295	$13K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,293	2,960	$12K
87563		<1%	635	593	$11K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	635	593	$11K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	142	127	$10K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	611	571	$10K

25 more codes

87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	609	$10K
87634		<1%	303	$8K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	298	$7K
80061	Lipid panel	<1%	1,209	$7K
84443	Thyroid stimulating hormone (TSH)	<1%	963	$6K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,097	$4K
87086	Culture, bacterial; quantitative colony count, urine	<1%	465	$2K
80048	Basic metabolic panel (calcium, ionized)	<1%	850	$1K
87498		<1%	84	$1K
87481		<1%	14	$1K
36415	Collection of venous blood by venipuncture	<1%	3,212	$776.14
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	67	$753.02
87529		<1%	19	$717.95
87653		<1%	13	$197.70
87640		<1%	13	$197.70
86769		<1%	32	$192.96
82607		<1%	28	$147.67
80164		<1%	32	$117.46
80076		<1%	15	$99.51
87184		<1%	28	$53.58
87088		<1%	15	$32.46
81001		<1%	51	$25.24
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	888	$7.80
81050		<1%	12	$3.71
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	1,520	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBAILEY, JAMES (MANAGING PARTNER)

Same official

Other billing entities under BAILEY, JAMES

Full network →

Provider	Location	Paid
Wallowa Valley Eye Care, INC.	Enterprise, OR	$112K
Southern Eye Associates of SC, PA	Greer, SC	$9K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.